| (Values in U.S. Thousands) | Dec, 2022 | Sep, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 |
| Sales | 0 | 0 | 20 | 0 | 140 |
| Sales Growth | unch | -100.00% | unch | -100.00% | unch |
| Net Income | -3,060 | -3,810 | -2,620 | -2,850 | 10,620 |
| Net Income Growth | +19.69% | -45.42% | +8.07% | -126.84% | +529.96% |
Nanomix Corp (NNMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Nanomix Corporation is involved in the development of mobile, affordable, point-of-care diagnostics. The company's products are designed to impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings. Nanomix Corporation, formerly known as Boston Therapeutics Inc., is based in EMERYVILLE, Calif.
Fiscal Year End Date: 12/31